KIVU-305

KIVU-305 is an antibody-drug conjugate (topoisomerase inhibitor payload, DAR4) from Kivu Bioscience. A humanised, Fc-silenced CEACAM5 antibody joined by site-specific GlycoConnect conjugation to a HydraSpace-linked SYNtecan E topoisomerase inhibitor payload at a drug-to-antibody ratio of 4. Its furthest stage is phase 1, for colorectal cancer, pancreatic cancer, gastric cancer and lung cancer. ClinicalTrials.gov registers it in one study linked below. Whether it works in people has not been established unless a trial below reports it.